Eli Lilly (NYSE: LLY) delivered a second-quarter earnings report, and it’s difficult to find anything to criticize. The pharmaceutical giant beat both revenue and earnings estimates, and shares have climbed approximately 7% in the two trading sessions since the company issued the report on Aug. 4 before the market opened.
The headline numbers speak for themselves. Total revenue reached $23 billion, up 48% year-over-year. Non-GAAP earnings per share came in at $8.38, a 33% increase from the prior-year period. Both figures topped what Wall Street had penciled in heading into the print.
What makes this quarter notable is timing. Lilly is now lapping some of its toughest GLP-1 comparisons yet, as Mounjaro and Zepbound sales exploded a year ago. Growth accelerating anyway, rather than decelerating, tells investors something important about durability.
Beyond the weight-loss and diabetes franchise, Lilly’s broader pipeline is starting to contribute meaningfully. Oncology, immunology, and neuroscience products posted a combined growth of 121%. Management also raised full-year guidance on both revenue and profitability. The stock’s premium valuation increasingly looks justified by execution, not just narrative.
GLP-1 Momentum Shows No Signs of Slowing
The GLP-1 (incretin) franchise remains the engine driving Lilly’s results, and the Q2 numbers made that unmistakably clear. Overall revenue grew 67% year-over-year, fueled by both market expansion and Lilly gaining share from competitors. Mounjaro alone generated $9.9 billion in quarterly sales, up 91% from a year ago. Zepbound added $4.9 billion, a 46% increase.
Market share data reinforces the trend. Lilly now commands 60.9% of the U.S. incretin analog market, up from a smaller base a year prior. Internationally, the company holds 54.9% share, also expanding. Novo Nordisk’s share has been sliding in both markets as Lilly’s products continue winning new prescriptions.
Access is widening as well. The company’s Medicare GLP-1 Bridge program now covers an estimated 20 million potentially eligible patients, with beneficiaries paying just $50 per month out of pocket. Roughly 60% to 70% of program participants are new incretin starts, not existing patients switching therapies. That’s a meaningful signal that the total addressable market continues to grow rather than simply consolidating around existing players.
Foundayo, Lilly’s oral GLP-1, is still in its early innings but has already generated $98 million in its first reported quarter, with international launches underway in the UAE, Mexico, and Saudi Arabia.
A Deepening Pipeline Reduces Reliance on One Drug Class
Investors who worried about Lilly’s dependence on GLP-1 medications got a partial answer this quarter. Key product revenue in oncology, immunology, and neuroscience grew a combined 121% year-over-year. That’s a meaningful diversification signal, even if the dollar amounts remain small relative to the diabetes and obesity franchise.
Jaypirca, Lilly’s blood cancer therapy, posted a 56% sales increase and secured approval for line-agnostic use in chronic lymphocytic leukemia in the European Union. Ebglyss, an immunology asset, grew sales 131% year-over-year following approval for less-frequent maintenance dosing, a change that should improve patient adherence.
Retatrutide, viewed by many analysts as Lilly’s next major cardiometabolic asset, delivered strong data across its TRIUMPH trial program. Patients achieved weight loss of up to 28.3% at the highest dose tested in one obesity trial, with consistent results across trials targeting different comorbidities. Regulatory submissions for retatrutide are now expected in 2027.
Lilly also continued an aggressive acquisition strategy, announcing or completing four deals this quarter spanning oncology, neuroscience, immunology, and infectious disease.
Technical Picture Reflects the Fundamental Strength
LLY’s chart tells a similar story to the earnings print. Shares have climbed from below $800 last September to nearly $1,200 currently, trading well above its 200-day simple moving average near $1,031. That’s a textbook sign of sustained institutional buying.
The MACD indicator shows a bullish crossover forming, with the MACD line moving above the signal line after a brief consolidation period through late July. Volume on the earnings reaction session came in elevated relative to recent averages.
A Stock That’s Earned Its Premium, For Now
Lilly’s guidance update reinforces the bullish case. Full-year revenue guidance rose to a range of $85 billion to $87 billion, up from $82 billion to $85 billion previously. Management did flag potential deceleration in the coming quarters, tied to prior-period adjustments and seasonal patterns.
That caution matters less than it might sound. Any slowdown would come off a dramatically higher revenue base than a year ago. Analysts have continued raising price targets following the report. Whether Lilly proves to be a true “forever stock” remains an open question, but right now, the fundamentals are doing the talking.
